research Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
Search
forResearch
3 / 1000+ results
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
Experts
1 / 1 results
Clinics
1 / 1 resultsLearn
— no results
Community Join
— no results